These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 65452)

  • 1. Intensive immunosuppression with cyclophosphamide in multiple sclerosis. Follow up of 110 patients for 2-6 years.
    Gonsette RE; Demonty L; Delmotte P
    J Neurol; 1977 Feb; 214(3):173-81. PubMed ID: 65452
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of intensive immunosuppression on the course of chronic progressive multiple sclerosis.
    Hommers OR; Lamers KJ; Reekers P
    J Neurol; 1980; 223(3):177-90. PubMed ID: 6157011
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Experience with cyclophosphamide in multiple sclerosis: the cons.
    Likosky WH
    Neurology; 1988 Jul; 38(7 Suppl 2):14-8. PubMed ID: 3290708
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cyclophosphamide in relapsing remitting multiple sclerosis.
    D'Andrea F; D'Aurizio C; Marini C; Prencipe M
    Ital J Neurol Sci; 1990 Jun; 11(3):271-4. PubMed ID: 2387697
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Short-term intensive cyclophosphamide treatment in progressive multiple sclerosis.
    Siracusa GF; Amato MP; Fratiglioni L; Sità D; Amaducci L
    Ital J Neurol Sci; 1987 Dec; 8(6):589-92. PubMed ID: 3429217
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The effect of cyclophosphamide on T lymphocytes and T lymphocyte subsets in patients with chronic progressive multiple sclerosis.
    Brinkman CJ; Nillesen WM; Hommes OR
    Acta Neurol Scand; 1984 Feb; 69(2):90-6. PubMed ID: 6231801
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Intensive immunosuppression in progressive multiple sclerosis. An open study comparing 3 groups: cyclophosphamide, cyclophosphamide-plasmapheresis and control subjects. Results after 3 years].
    Trouillas P; Neuschwander P; Nighoghossian N; Adeleine P; Tremisi P
    Rev Neurol (Paris); 1989; 145(5):369-77. PubMed ID: 2662340
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intense immunosuppression in chronic progressive multiple sclerosis: the Kaiser study.
    Likosky WH; Fireman B; Elmore R; Eno G; Gale K; Goode GB; Ikeda K; Laster J; Mosher C; Rozance J
    J Neurol Neurosurg Psychiatry; 1991 Dec; 54(12):1055-60. PubMed ID: 1783915
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Short-term intensive cyclophosphamide treatment in multiple sclerosis. A retrospective controlled study.
    Theys P; Gosseye-Lissoir F; Ketelaer P; Carton H
    J Neurol; 1981; 225(2):119-33. PubMed ID: 6164763
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Moving on to second-line therapies in pediatric MS: Immunosuppression with cyclophosphamide.
    Yeh EA; Weinstock-Guttman B
    Neurology; 2009 Jun; 72(24):2064-5. PubMed ID: 19439721
    [No Abstract]   [Full Text] [Related]  

  • 11. [Late results of the treatment of the chronic progressive form of multiple sclerosis by intensive immunosuppression].
    Wender M; Tokarz-Kupczyk E; Mularek O
    Neurol Neurochir Pol; 1989; 23(3):188-92. PubMed ID: 2561379
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Experience with the use of cyclophosphamide in multiple sclerosis].
    Bel'man EL; Gordeev IaIa
    Zh Nevropatol Psikhiatr Im S S Korsakova; 1977; 77(2):201-4. PubMed ID: 842238
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cyclophosphamide levels in serum and spinal fluid of multiple sclerosis patients treated with immunosuppression.
    Hommes OR; Aerts F; Bahr U; Schulten HR
    J Neurol Sci; 1983 Feb; 58(2):297-303. PubMed ID: 6834081
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Immunosuppressive treatment in multiple sclerosis].
    Oliveira TV; Gorz-Reinhardt AM; Gracia CM; Bittencourt PR
    Arq Neuropsiquiatr; 1992 Sep; 50(3):295-301. PubMed ID: 1308406
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mitoxantrone: a review of its use in multiple sclerosis.
    Scott LJ; Figgitt DP
    CNS Drugs; 2004; 18(6):379-96. PubMed ID: 15089110
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunosuppression with high-dose i.v. cyclophosphamide and ACTH in progressive multiple sclerosis: cumulative 6-year experience in 164 patients.
    Carter JL; Hafler DA; Dawson DM; Orav J; Weiner HL
    Neurology; 1988 Jul; 38(7 Suppl 2):9-14. PubMed ID: 2838768
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of immunosuppressive agents and particularly of cyclophosphamide on lymphocytes subsets in treated multiple sclerosis patients.
    Gonsette RE; Defalque A; Demonty L
    Riv Neurol; 1987; 57(3):181-4. PubMed ID: 2960008
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunologic effects of cyclophosphamide/ACTH in patients with chronic progressive multiple sclerosis.
    Hafler DA; Orav J; Gertz R; Stazzone L; Weiner HL
    J Neuroimmunol; 1991 May; 32(2):149-58. PubMed ID: 1672870
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunoablation and autologous haemopoietic stem-cell transplantation for aggressive multiple sclerosis: a multicentre single-group phase 2 trial.
    Atkins HL; Bowman M; Allan D; Anstee G; Arnold DL; Bar-Or A; Bence-Bruckler I; Birch P; Bredeson C; Chen J; Fergusson D; Halpenny M; Hamelin L; Huebsch L; Hutton B; Laneuville P; Lapierre Y; Lee H; Martin L; McDiarmid S; O'Connor P; Ramsay T; Sabloff M; Walker L; Freedman MS
    Lancet; 2016 Aug; 388(10044):576-85. PubMed ID: 27291994
    [TBL] [Abstract][Full Text] [Related]  

  • 20. DIAS rounds. Cyclophosphamide in multiple sclerosis.
    Mason G; Hart LL
    Drug Intell Clin Pharm; 1984 Mar; 18(3):215-6. PubMed ID: 6697883
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.